You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Increasing Access and Developing Predictors for Colorectal Cancer Screening for Minority and Medicaid Clients

    SBC: Witness CARES, LLC            Topic: 102

    ABSTRACT African Americans have 22% higher incidence and 49% higher death rates from CRC than any other ethnic/racial group. Similarly, lower socioeconomic status (SES) is also associated with higher CRC incidence and mortality. Both of these groups are overrepresented in Medicaid populations. Screening colonoscopy is a cost-effective cancer prevention and control strategy, leading to CRC preventi ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Image-Based Quantification and Analysis of Longitudinal Lung Nodule Deformations

    SBC: KITWARE INC            Topic: NIBIB

    DESCRIPTION (provided by applicant): Image-based evaluation of pathologies over time is complicated by variability in image acquisition and patient positioning, deformations due to respiratory and cardiac motion, and the clinical standard in radiology of comparing unaligned images. This application proposes a computational method for longitudinal image analysis that captures, illustrates and quant ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Conversations About Cancer (CAC): A Theatrical Production

    SBC: KLEIN BUENDEL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Over the past decade, an investigation of how family members talk through cancer on the telephone has resulted in the recent publication of a lengthy volume entitled A Natural History of Family Cancer: Interactional Resources for Managing Illness (NH). Based on the conversations analyzed for this volume, and related research on the psychosocial impacts and con ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Peptidomic Rapid Point-of-Care TB Diagnostic

    SBC: NEW YORK UNIVERSITY            Topic: NIAID

    DESCRIPTION (provided by applicant): The goals of this proposal are to devise rapid serological tests that can replace the sputum smear test for the diagnosis of active TB and meets the WHO specifications to replace microscopy in resource-limited countries based on immunodominant peptides from three M. tb cell-wall proteins. Although direct smear microscopy is highly specific, the test is tedious, ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. A Synthetic Human Cytomegalovirus Vaccine Platform

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government